Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-30T15:18:54.269Z Has data issue: false hasContentIssue false
  • English
  • Français

Frisium

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 4 , November 1997 , pp. A-49
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

References:

1.Schmidt, D & Gram, LMonotherapy versus polytherapy in epilepsy. CNS Drugs 1995; 3:194–208.CrossRefGoogle Scholar
2.Brodie, MJ. Lamotrigine - An update. Can J Neurol Sci 1996; 23(Suppl. 2):S6-S9.CrossRefGoogle ScholarPubMed
3.Product Monograph of LAMICTAL (lamotrigine), Glaxo Wellcome Inc. 1997.Google Scholar
4.Faught, E. Lamotrigine monotherapy in patents with refractory partial-onset seizures. In. Loiseau, P (ed.) Lamotrigine. A Brighter Future. International Congress and Symposium Series 214. London: The Royal Society of Medicine Press; 1996:3742.Google Scholar
5.Perucca, E. Add-on trial of lamotrigine followed by withdrawal of concomitant medication and stabilization on monotherapy. In. Loiseau, P (ed.) Lamotrigine. A Brighter Future. International Congress and Symposium Series 214. London: The Royal Society of Medicine Press; 1996:23–30.Google Scholar
6.Brodie, MJ. Lamotrigine monotherapy an overview. In. Loiseau, P (ed.) Lamotrigine - A Brighter Future. International Congress and Symposium Series 214. London: The Royal Society of Medicine Press; 1996:43–49.Google Scholar